NCT03196401View on ClinicalTrials.gov

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 27, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Solitary Bone Plasmacytoma
Interventions
DRUG

Durvalumab

durvalumab 1500mg administered intravenously every 28 days, for a total of six doses

RADIATION

Radiation therapy

concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memoral Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03196401 - A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma | Biotech Hunter | Biotech Hunter